Mesa and Ulmer Measure Methods for JAK Inhibitor Optimization in Myelofibrosis
Season 4, Episode 7, Nov 19, 2020, 10:03 PM
Share
Subscribe
In our exclusive interview, Dr. Mesa and Dr. Ulmer discuss the current roles of ruxolitinib and fedratinib in myelofibrosis, current guidance for JAK inhibitor dosing, the utility of re-exposure to JAK inhibitors, and clinical trial options.